Quarterly Result6 May 2025, 02:01 pm
Alembic Pharmaceuticals Reports 17% Increase in Net Revenue for Q4 2025
AI Summary
Alembic Pharmaceuticals Limited has announced its consolidated financial results for the fourth quarter ended 31st March, 2025. The company reported a 17% increase in net sales, reaching Rs. 1770 Cr. EBITDA was up by 9% to Rs. 286 Cr., with an EBITDA margin of 16% of sales. Profit before tax increased by 5% to Rs. 192 Cr., and net profit stood at Rs. 157 Cr. The India-Branded Business grew by 8% to Rs. 545 Cr., with specialty therapies and trusted brands driving the growth. The Animal Health division also grew by 19%. The US business grew by 20%, and the Ex-US business grew by 43%. The API business grew by 4% to Rs. 342 Cr. The company has a strong pipeline of products and is committed to consistent growth.
Key Highlights
- Net Sales increased by 17% to Rs. 1770 Cr.
- EBITDA up by 9% to Rs. 286 Cr.
- Profit Before Tax up by 5% to Rs. 192 Cr.
- Animal Health business grew by 19% for the quarter.
- US business grew by 20% during the quarter.